Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.
Dr. John Cush RheumNow
4 years ago
Hyperuricemia is assoc w/ adverse CV events in cardiac pts. ALL-HEART study Rx 5721 ischemic heart pts (no gout) w/ usual care of allopurinol. After 4·8 yrs F/U, there was no difference in cardiac outcomes. No allopurinol benefit in IHD https://t.co/1vS94pDs1B https://t.co/koAGpPrX7H
Dr. John Cush RheumNow
4 years ago
Analysis of WHO Safety Vigibase found 625 cases of drug-induced SLE - mostly female (78%), 59 yrs old, w/ half suspecting only PPI. Most common was Omeprazole (30%). Another 800K French database ID 39 pts w/ PPI CLE, half SCLE, 5% DLE https://t.co/vfAArCfWW1 https://t.co/3xQc5NZhvQ
Dr. John Cush RheumNow
4 years ago
Hydroxychloroquine Dosing and SLE Flares
A cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares.
https://t.co/VCn4hOs1PY https://t.co/bbVeVlD1u0
Dr. John Cush RheumNow
4 years ago
ACR Award Winners
Dr. Cush reviews the news and journal reports from the past week on RheumNow.
Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
https://t.co/tJTPtEPiyX https://t.co/w2DgjeGOtb
Dr. John Cush RheumNow
4 years ago
Efficacy of Shingrix Vaccine lasts for 10 yrs. Shingrix was approved in 2017 based on 2 Lg RCTs showing 6 yr. protective efficacy of 97% (ages>50) * 91% (age >70). Long-term F/U shows 81.6% effectfor mean of 9.6 (±0.3) years post-vaccination https://t.co/qCHZ4fUm35 https://t.co/LfYROtN1xZ
Dr. John Cush RheumNow
4 years ago
Spondyloenchondrodysplasia - Very rare genetic skeletal dysplasia w/ short stature, platyspondyly, short broad ilia and enchondromas in long bones or pelvis. Varied phenotype w/ CNS (spasticity, retardation) & autoimmune (ITP, SLE, AIHA, thyroiditis) https://t.co/4DHqohjb2Z https://t.co/Bafh1v0MOA
Dr. John Cush RheumNow
4 years ago
NEJM: Dysphagia Due to Diffuse Idiopathic Skeletal Hyperostosis - 70yoM with 6-month history of dysphagia. Compression of the hypopharyx by large cervical osteophytes was seen in a videofluoroscopic swallowing study https://t.co/lp93QwiZlz https://t.co/jI070aQB2F
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.
Dr. John Cush RheumNow
4 years ago
Dr. Kent Kwoh and Researchers at the University of Arizona Arthritis Center have been awarded a $3.4 million grant from the National Institutes of Health to undertake a study that seeks to identify determinants of rapid knee deterioration in OA https://t.co/K9wxRzmVnw https://t.co/nM7ByxKikB
Dr. John Cush RheumNow
4 years ago
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/mEkaa7Yjt1 https://t.co/BaMYHiG5Pb
Catherine Sims, MD DrCassySims
4 years ago
Highlights from the @ACRheum Kawasaki Disease Guidelines
🥇IVIG is mainstay therapy (2 g/kg)
👶🏼 Use ASA in acute KD
🗣Refractory cases may require steroids or additional immunosuppression
🫀Get echos on all patients to assess for coronary aneurysms
Dr. John Cush RheumNow
4 years ago
Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etoricoxib (2.69% vs 8.51% not taking). Both Celebrex/Etoricoxib significantly reduced stroke risk p < 0.001 https://t.co/6idrH9g0LJ https://t.co/d80bEtsP7k
Dr. John Cush RheumNow
4 years ago
FDA has approves RINVOQ (upadacitinib) for the treatment of Active Non-Radiographic Axial Spondyloarthritis https://t.co/DMuQFjFdrf https://t.co/zLsniZ2zOg
